TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07158918: ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

Sponsor: ABL Bio, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 65 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,335,180

Rescue Site Savings

+$863,940

Unlock Full NCT07158918 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07158918 Rescue Dossier →